Australian Natural Therapeutics Group (ANTG)

Inspired by a global shift towards medical cannabis and driven by his father 'Rocky's' battle with cancer, Matt Cantelo founded ANTG to transform pain relief through premium Australian-grown plant medicine. 'Rocky's' legacy now thrives in ANTG's award-winning cannabis strains, symbolizing a breakthrough in health outcomes and a relentless pursuit of scientific innovation and societal acceptance.

Australian Natural Therapeutics Group (ANTG) is a privately owned medicinal cannabis company based in Brisbane, producing pharmaceutical-grade cannabinoid-based medicinal treatments to patients in Australia and select overseas markets including, New Zealand, Germany and the UK. ANTG is a globally aligned and vertically integrated business, with operations spanning R&D, Cultivation, Manufacturing, and Distribution of branded ‘Australian Natural’ products and imported “Global Selects” products.

The existing operation is highly scalable, profitable and operationally cash flow positive. Thanks to their strong global partnerships and world-class facilities, ANTG is well equipped to service both the Australian and European markets.

Investment Highlights

Profitable Growth
ANTG reported significant financial achievements in FY23, with revenue growth of 11% to $21 million, positive operating cash flows and $2m of EBITDA. They have consolidated their growth through the successful acquisition of a $6.5 million facility in Brisbane to meet their growing demand.
Industry Tailwinds
The Australian medicinal cannabis market is expected to reach $1.0 billion by 2024 and the European market is expected to reach $4.8 billion by 2025. ANTG is perfectly positioned to leverage strong industry tailwinds in both these markets and are one of the few accredited manufacturers to be able to service both.
Best in Class R+D
ANTG holds a dedicated genetic research site in Australia to develop extracts with potential therapeutic benefits for cancer, dementia, and IBS.
Supportive Regulation
ANTG boasts a growing patient base exceeding 150,000 thanks to an upsurge in approvals and a higher demand for flower prescriptions. Additionally, the number of qualified prescribers has significantly increased due to streamlined regulations.

ANTG is poised for substantial growth across several fronts. Its newly acquired Brisbane facility is primed for expansion, boosting both cultivation capacity and output. Upgrades promise further production efficiency and cost reduction. Additionally, strategic partnerships with external growers will capture expanding demand.

The company is also innovating by developing new product formats alongside an over-the-counter product, catering to evolving market needs and regulations. This multi-pronged approach positions ANTG for significant growth in the medical cannabis space.

Raising funds will provide ANTG with working capital to support ongoing expansion activities ahead of a larger capital raise anticipated in Q2 FY24 which will fund more expansionary projects.